Survival benefit of mantle cell lymphoma patients enrolled in clinical trials; a joint study from the LYSA group and French cancer registries.
Fiche publication
Date publication
octobre 2017
Journal
Journal of cancer research and clinical oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BERTAUT Aurélie, Pr MAYNADIE Marc, Dr WORONOFF Anne-Sophie
Tous les auteurs :
Augustin A, Le Gouill S, Gressin R, Bertaut A, Monnereau A, Woronoff AS, Trétarre B, Delafosse P, Troussard X, Moreau A, Hermine O, Maynadié M
Lien Pubmed
Résumé
Mantle cell lymphoma (MCL) is a rare non-Hodgkin's lymphoma entity with a poor prognosis. Therapeutic advances have improved the survival of patients enrolled in clinical trials; however, their impact on patients outside clinical trials remains unclear. In this work, we compared patient outcome inside and outside clinical trials.
Mots clés
Clinical trial inclusion, Mantle cell lymphoma, Non-Hodgkin’s lymphoma, Population-based registry, Prognostic factors
Référence
J. Cancer Res. Clin. Oncol.. 2017 Oct;: